A citation-based method for searching scientific literature

Jingjing Cai, Meng Xu, Xiaojing Zhang, Hongliang Li. Annu Rev Pathol 2019
Times Cited: 44







List of co-cited articles
649 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Hepatology 2019
94
40

The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.
Yan-Xiao Ji, Zan Huang, Xia Yang, Xiaozhan Wang, Ling-Ping Zhao, Pi-Xiao Wang, Xiao-Jing Zhang, Michele Alves-Bezerra, Lin Cai, Peng Zhang,[...]. Nat Med 2018
82
36

The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.
Peng Zhang, Pi-Xiao Wang, Ling-Ping Zhao, Xin Zhang, Yan-Xiao Ji, Xiao-Jing Zhang, Chun Fang, Yue-Xin Lu, Xia Yang, Mao-Mao Gao,[...]. Nat Med 2018
121
36


Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.
Ze Chen, Yao Yu, Jingjing Cai, Hongliang Li. Trends Endocrinol Metab 2019
60
34

Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Trends Endocrinol Metab 2018
45
29

Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.
Guang-Nian Zhao, Peng Zhang, Jun Gong, Xiao-Jing Zhang, Pi-Xiao Wang, Miao Yin, Zhou Jiang, Li-Jun Shen, Yan-Xiao Ji, Jingjing Tong,[...]. Nat Med 2017
93
29

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.
Pi-Xiao Wang, Yan-Xiao Ji, Xiao-Jing Zhang, Ling-Ping Zhao, Zhen-Zhen Yan, Peng Zhang, Li-Jun Shen, Xia Yang, Jing Fang, Song Tian,[...]. Nat Med 2017
145
29


Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
27

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
27

The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.
Feng-Juan Yan, Xiao-Jing Zhang, Wen-Xin Wang, Yan-Xiao Ji, Pi-Xiao Wang, Yang Yang, Jun Gong, Li-Jun Shen, Xue-Yong Zhu, Zan Huang,[...]. Hepatology 2017
53
25

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases.
Yao Yu, Jingjing Cai, Zhigang She, Hongliang Li. Adv Sci (Weinh) 2018
80
25

Innate immune regulatory networks in hepatic lipid metabolism.
Lan Bai, Hongliang Li. J Mol Med (Berl) 2019
35
31

Progress and challenges in the prevention and control of nonalcoholic fatty liver disease.
Jingjing Cai, Xiao-Jing Zhang, Hongliang Li. Med Res Rev 2019
69
22

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
22

Epidemiological Features of NAFLD From 1999 to 2018 in China.
Jianghua Zhou, Feng Zhou, Wenxin Wang, Xiao-Jing Zhang, Yan-Xiao Ji, Peng Zhang, Zhi-Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li. Hepatology 2020
161
22

Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling.
Pi-Xiao Wang, Xiao-Jing Zhang, Pengcheng Luo, Xi Jiang, Peng Zhang, Junhong Guo, Guang-Nian Zhao, Xueyong Zhu, Yan Zhang, Sijun Yang,[...]. Nat Commun 2016
95
20

Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Juan Pablo Arab, Marco Arrese, Michael Trauner. Annu Rev Pathol 2018
248
20

Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
Jingjing Cai, Xiao-Jing Zhang, Yan-Xiao Ji, Peng Zhang, Zhi-Gang She, Hongliang Li. Circ Res 2020
78
20

Interferon regulatory factor 3 constrains IKKβ/NF-κB signaling to alleviate hepatic steatosis and insulin resistance.
Xin-An Wang, Ran Zhang, Zhi-Gang She, Xiao-Fei Zhang, Ding-Sheng Jiang, Tao Wang, Lu Gao, Wei Deng, Shu-Min Zhang, Li-Hua Zhu,[...]. Hepatology 2014
108
18

DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.
Lanfeng Xie, Pi-Xiao Wang, Peng Zhang, Xiao-Jing Zhang, Guang-Nian Zhao, Aibing Wang, Junhong Guo, Xueyong Zhu, Qin Zhang, Hongliang Li. J Hepatol 2016
48
18

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis.
Mei Xiang, Pi-Xiao Wang, Ai-Bing Wang, Xiao-Jing Zhang, Yaxing Zhang, Peng Zhang, Fang-Hua Mei, Man-Hua Chen, Hongliang Li. J Hepatol 2016
99
18

Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor γ in Mice.
Jingjing Tong, Cui-Juan Han, Jia-Zhen Zhang, Wen-Zhi He, Guo-Jun Zhao, Xu Cheng, Lei Zhang, Ke-Qiong Deng, Ye Liu, Hui-Fen Fan,[...]. Hepatology 2019
27
29

Reprogramming Innate Immune Signaling in Cardiometabolic Disease.
Yaxing Zhang, Xiao-Jing Zhang, Pi-Xiao Wang, Peng Zhang, Hongliang Li. Hypertension 2017
19
42

Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1.
Yutao Wang, Huan Wen, Jiajun Fu, Lin Cai, Peng-Long Li, Chang-Ling Zhao, Zhu-Feng Dong, Jun-Peng Ma, Xi Wang, Han Tian,[...]. Hepatology 2020
42
19

Hepatic Oncostatin M Receptor β Regulates Obesity-Induced Steatosis and Insulin Resistance.
Pengcheng Luo, Pi-Xiao Wang, Zuo-Zhi Li, Xiao-Jing Zhang, Xi Jiang, Jun Gong, Juan-Juan Qin, Junhong Guo, Xueyong Zhu, Sijun Yang,[...]. Am J Pathol 2016
26
26

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.
Yan-Xiao Ji, Peng Zhang, Xiao-Jing Zhang, Yi-Chao Zhao, Ke-Qiong Deng, Xi Jiang, Pi-Xiao Wang, Zan Huang, Hongliang Li. Nat Commun 2016
120
15

Time to step-up the fight against NAFLD.
Xiao-Jing Zhang, Zhi-Gang She, Hongliang Li. Hepatology 2018
24
29

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Scott L Friedman, Vlad Ratziu, Stephen A Harrison, Manal F Abdelmalek, Guruprasad P Aithal, Juan Caballeria, Sven Francque, Geoffrey Farrell, Kris V Kowdley, Antonio Craxi,[...]. Hepatology 2018
406
15

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Rohit Loomba, Eric Lawitz, Parvez S Mantry, Saumya Jayakumar, Stephen H Caldwell, Hays Arnold, Anna Mae Diehl, C Stephen Djedjos, Ling Han, Robert P Myers,[...]. Hepatology 2018
348
15

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
15

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis.
Feng Zhou, Jianghua Zhou, Wenxin Wang, Xiao-Jing Zhang, Yan-Xiao Ji, Peng Zhang, Zhi-Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li. Hepatology 2019
223
15

Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.
Ling Gao, Pi-Xiao Wang, Yaxing Zhang, Chang-Jiang Yu, Yanxiao Ji, Xiaozhan Wang, Peng Zhang, Xi Jiang, Hong Jin, Zan Huang,[...]. J Hepatol 2016
36
16

Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
Li-Hua Zhu, Aibing Wang, Pengcheng Luo, Xinan Wang, Ding-Sheng Jiang, Wei Deng, Xiaofei Zhang, Tao Wang, Yi Liu, Lu Gao,[...]. J Hepatol 2014
41
14

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
J Ludwig, T R Viggiano, D B McGill, B J Oh. Mayo Clin Proc 1980
13

Reprogramming Interferon Regulatory Factor Signaling in Cardiometabolic Diseases.
Yaxing Zhang, Hongliang Li. Physiology (Bethesda) 2017
22
27

Triggering and resolution of inflammation in NASH.
Susanne Schuster, Daniel Cabrera, Marco Arrese, Ariel E Feldstein. Nat Rev Gastroenterol Hepatol 2018
342
13

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
13

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
975
13

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
653
13

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
13

F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice.
Lan Bai, Ming-Ming Chen, Ze-Dong Chen, Peng Zhang, Song Tian, Yan Zhang, Xue-Yong Zhu, Ye Liu, Zhi-Gang She, Yan-Xiao Ji,[...]. Hepatology 2019
28
21


Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.
Ruth C R Meex, Matthew J Watt. Nat Rev Endocrinol 2017
298
13

Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension.
Yan-Ci Zhao, Guo-Jun Zhao, Ze Chen, Zhi-Gang She, Jingjing Cai, Hongliang Li. Hypertension 2020
61
13

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
13

Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.
Chongshu Jian, Jiajun Fu, Xu Cheng, Li-Jun Shen, Yan-Xiao Ji, Xiaoming Wang, Shan Pan, Han Tian, Song Tian, Rufang Liao,[...]. Cell Metab 2020
45
13

Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease.
Ze Chen, Ruifeng Tian, Zhigang She, Jingjing Cai, Hongliang Li. Free Radic Biol Med 2020
273
13

Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges.
Yaxing Zhang, Xiao-Jing Zhang, Hongliang Li. Curr Drug Targets 2017
13
38


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.